RCUS
$22.59
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Recent News
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage
Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker analyses that support casdatifan’s mechanism and potential clinical benefit in kidney cancer patients. Arcus also highlighted progress across its broader oncology and inflammation pipeline, with multiple Phase 3 programs underway or planned. For you as an investor, this update puts the clinical...
Arcus Biosciences Q4 Earnings Call Highlights
Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for late-stage development in clear cell renal cell carcinoma (ccRCC). Management also discussed an emer
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.